A pilot study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and folinic acid for colorectal liver metastases

Oncology

Volumn 55, Issue 1, 1997, Pages 53-58

  Lorenz, M ^a   Staib Sebler, E ^a   Gog, C ^a   Petrowsky, H ^a   Kohne C H ^b   Encke, A ^a  

^a GOETHE UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

5 fluorouracil; Folinic acid; Hepatic arterial infusion; Hepatic metastases; High dose therapy; Metastatic colorectal carcinoma; Second line treatment

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HEPARIN; LIQUIMIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; PAIN; PILOT STUDY; PRIORITY JOURNAL; SKIN MANIFESTATION; VOMITING; COLORECTAL TUMOR; DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0030666166     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011835     Document Type: Article

References (26)

1. Rougier PH, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, Faivre J, Fondation Française de Cancerologie Digestive: Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995;82:1397-1400.
2. Scheithauer W, Rosen H, Kornek GV, Sebasta C, Depisch D: Randomised comparison of a combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306: 752-755.
3. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 1989;7:1437-1446.
4. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
5. The Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:869-903.
6. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954;30:227-230.
7. Ackerman NB, Lien W, Kondi EB, Silverman NA: The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to small and large tumors. Surgery 1969;66:1067-1072.
8. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-258.
9. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G, Frei E: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-3792.
10. Balch CM, Urist MM, Soong SJ, McGregor M: A prospective phase II clinical trial of continuous FUdR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 1983; 198:567-573.
11. Herrmann G, Lorenz M, Kirkowa-Reimann M, Hottenrott C, Hübner K: Morphological changes after intra-arterial chemotherapy of the liver. Hepatogastroenterology 1987:34:5-9.
12. Hohn DC, Rayner AA, Economou JS, Ignoffo RJ, Lewis BJ, Stagg R: Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 1986; 57:465-470.
13. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morell L, Feun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;4:625-630.
14. Jäger E, Klein O, Wächter B, Müller B, Braun U, Knuth A: Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment. Oncology 1995;52:470-473.
15. Köhne CH, Wilke H, Hecker H, Schöffski P, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaasen U, Westernhausen M, Hiddemann W, Hennemann B, Schott G, Bade J, Strohmeyer G, Harstrick A, Schubert U, Bokemeyer C, Schmoll HJ: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann Oncol 1995;6:461-466.
16. Curley SA, Hohn DC, Roh MS: Hepatic artery infusion pumps: Cannulation techniques and other surgical considerations. Langenbecks Arch Chir 1990;375:119-124.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-462.
19. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P: Intrahepatic or systemic infusion of fluorodeoxyundine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987;107:459-465.
20. Rougier PH, Laplanche A, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet JC, Gallot D, Gouzi JL, Paillier JL, Elias D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:112-118.
21. Link KH, Kreuser ED, Safi F: Die intraarterielle Chemotherapie mit 5-FU und Folinsäure (FA, Rescuvolin®) im Therapiekonzept bei nicht resektablen kolorektalen Lebermetastasen. Ein Vergleich von 5-FU/FA i.v. vs. 5-FU/ FA i.a. vs. 5-FUdR i.a. oder 5-FUdR i.a. + i.v. Tumordiagn Ther 1993;14:224-231.
22. Staib-Sebler E, Lorenz M, Gog C, Encke A: Continuous arterial 5-fluorouracil and folinic acid chemotherapy for colorectal liver metastases. Onkologie 1995;18:240-244.
23. Schlag P, Hohenberger P, Hölting T, Buhl K, Schwarz V, Herfarth C: Hepatic arterial infusion (HAI) chemotherapy for liver metastases of colorectal cancer using 5-FU. Eur J Surg Oncol 1990;16:99-104.
24. Schallhorn A, Peyerl G, Denecke H: Pharmacokinetics of 5-fluorouracil during isolated liver perfusion. Reg Cancer Treat 1988;1:21-27.
25. Kerr DJ, Ledermann JA, Mc Ardle CS, Buckels J, Neoptolemos J, Seymour M, Doughty J, Budden J, Taylor I: Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol 1995; 13:2968-2972.
26. Anderson JH, Kerr DJ, Setanoians A: Pharmacokinetics of IHA folinic acid. Br J Cancer 1992;65:133-135.